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Abstract
Background: Regulated intramembranous proteolysis of the amyloid-b precursor protein by the c-secretase yields amyloid-
b, which is the major component of the amyloid plaques found in Alzheimer’s disease (AD), and the APP intracellular
domain (AID). In vitro studies have involved AID in apoptosis and gene transcription. In vivo studies, which utilize transgenic
mice expressing AID in the forebrain, only support a role for AID in apoptosis but not gene transcription.
Methodology/Principal Findings: Here, we have further characterized several lines of AID transgenic mice by crossing them
with human Tau-bearing mice, to determine whether over-expression of AID in the forebrain provokes AD-like pathologic
features in this background. We have found no evidence that AID overexpression induces AD-like characteristics, such as
activation of GSK-3b, hyperphosphorylation of Tau and formation of neurofibrillary pathology.
Conclusions/Significance: Overall, these data suggest that AID transgenic mice do not represent a model that reproduces
the overt biochemical and anatomo-pathologic lesions observed in AD patients. They can still be a valuable tool to
understand the role of AID in enhancing the cell sensitivity to apoptotic stimuli, whose pathways still need to be
characterized.
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Introduction
Alzheimer disease (AD) is characterized by the production of
amyloidogenic peptides, neurofibrillary tangles (NFT) and neuro-
degeneration[1,2].Theprevailingpathogenictheory,the‘‘Amyloid
CascadeHypothesis’’[3],positsthattheaccumulationofneurotoxic
amyloidogenic peptides triggers Tauopathy, neurodegeneration,
cognitive and behavioral changes. In AD, the amyloid lesions are
formed by Ab42, which derives from the Amyloid-b Precursor
Protein (APP). APP is cleaved by b-secretase to releases the soluble
b-ectodomain (sAPPb) and the membrane-bound COOH-terminal
fragment C99. C99 is in turn processed by c-secretase to produce
the APP intracellular domain (AID/AICD) and Ab peptides. More
recently, attention of researchers in the field has shifted from
Amyloid plaques to Ab42 oligomers as the main cause of AD
[4,5,6]. However, the amyloid cascade hypothesis is yet to be
validated, and causes of dementia may be multifaceted and involve
other mechanisms. Several investigators have suggested that other
APP-derived fragments may cause or contribute to AD pathogen-
esis. Evidence hints to specific functions and disfunctions for
holoAPP and APP-derived polypeptides. An APP fragment derived
from sAPPb interacts with DR6to trigger axonpruning and neuron
death [7]. The short AID/AICD is a biologically active intracellular
peptide, which modulates cell death, gene transcription and Ca
++
homeostasis [8,9,10,11,12,13,14,15,16,17,18,19]. Caspase-derived
APP fragments, such as C31 [20] and Jcasp [9,21], posses in vitro
toxic activities. Because of these evidence, various APP-derived
fragments,such as AID/AICD [10,22], C31[23], JCasp [9],sAPPb
[7] have been implicated in neurodegenerative processes.
Mouse models are critical to explore both pathogenesis and
therapy of human diseases. All animal models used to study
human neurodegenerative diseases consist of transgenic mice
carrying mutant forms of genes shown to be involved in human
dementia [24,25,26]. A serious limitation of these models is that
their design is predicated on the assumption that development of
amyloid plaques and neurofibrillary tangles is directly related to
the cognitive and behavioral changes associated with human
dementia. To determine whether AID could trigger an AD-like
neurodegenerative process in vivo, we have made transgenic mice
expressing AID-peptides in the CNS [27]. A previous analysis of
these mice showed that AID can modulate apoptosis in vivo.
However, a role of AID in gene transcription in vivo [28] could not
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transgenic mice to determine whether over-expression of AID in
the forebrain, when human Tau is also expressed, provokes AD-
like features, as recently suggested [22]. To this end, we have
crossed our AID lines with hTau mice [29,30] overexpressing
human Tau. We have chosen this model as it shows progressive,
age-related, Tau pathology in forebrain regions of the brain which
are also affected in human AD pathology (hippocampus,
parahippocampal cortex, frontal cortex etc.) and which overlap
with the pattern of expression of the AID transgene, without
necessarily expressing mutated Tau.
Materials and Methods
Ethics Statement
Mice were handled according to the Ethical Guidelines for
Treatment of Laboratory Animals of Albert Einstein College of
Medicine. The procedures were described and approved in animal
protocol number 20040707.
AID mice generation and crossing with hTau mice to
yield AID/hTau transgenic mice
AID mice were generated as described before [31]. Briefly, the
cDNA sequences corresponding to AID 50, 57 or 59, were
subcloned into the pNN vector, downstream of the 8Kb CamKIIa
promoter, driving the espression of the transgene in the forebrain
of the postnatal mouse [32]. Transgenic mice, initially on a FVB
background, were backcrosses, at least for 8 generations, onto the
C57Bl/6 background. hTau mice were obtained as described [29]
by crossing 8c mice, expressing a human Tau transgene, H1
haplotype driven by the Tau promoter [33], with Tau knock-out
(KO) mice that have a targeted disruption of exon 1 of Tau [34].
Animals were backcrossed 10 times to C57BL/6J background.
AID transgenic mice were crossed with hTau mice to yield mice
expressing AID transgene, human Tau transgene and one allele
copy of mouse Tau.
Monoclonal antibodies specific for Tau and Tau
phosphorylations
The following monoclonal antibodies have been produced as
described earlier [35].
DA9 (IgG1): total Tau aa102–140; TG5 (IgG1): total Tau
aa220–240 (murine and human); CP27 (Ig2B): total Tau aa130–
170 (human specific); CP13 (IgG1): pSer202; PHF1 (IgG1):
pSer396/Ser404; MC1 (IgG1): N-terminal conformational
change, Exon 10; CP17 (IgG3): pThr231; CP9 (IgM): pThr231.
Antibodies were used pure (hybridoma medium), purified or
biotinylated. Biotinylation of antibodies was performed using EZ-
Link NHS-PEO Solid Phase Biotinylation Kit (Pierce, # 21440).
Heat stable preparation for Tau
Mice were sacrificed by cervical dislocation after Isoflurane
anesthesia. One of the two brain hemispheres was processed for
protein and Tau extraction, the other for immunohistochemistry.
Forebrains were homogenized in 400mL/100mg of Homogenizing
Buffer (TBS-10mM TRIS, 140mM NaCl, pH 7.4-, Roche
Complete-EDTA Protease Inhibitor, 1mM PMSF, 1mM
Na3VO4, 10mM NaF, 2mM EGTA) for 200 with a Polytron
homogenizer, on ice. For heat stable Tau, to a 500mL aliquot of
homogenate, NaCl was added to 250mM, and bME was added to
5% final concentrations, and the mix vortexed. Homogenates
were heated at 100uC for 159, mixed again by vortexing and
cooled in ice for 309, vortexed briefly again and spun down at
20,000g for 109 at 4uC. The supernatant, containing heat stable
microtuble protein enriched for Tau, was retained and used for
subsequent experiments. Protein concentration was measured in
the original homogenate in order to load equal amounts of protein
for western blot and ELISA.
ELISA
Clear, flat bottom, 96 well plates were coated overnight with an
antibody specific for total Tau (DA9) 2mg/mL in Coating Buffer
(230mM K2HPO4, 135mM KH2PO4, 130mM NaCl, 2mM
EDTA, 0.05% NaN3, pH 7.2). Wells were blocked with 100%
Starting Block (Pierce) for 1 hour at room temperature. Homog-
enates were then added: brain homogenates, prepared as
described above, were mixed 1/1 with 0.1% SDS, briefly vortexed
and spun for 109 at 20,000g, at room temperature, and the
supernatant loaded on the ELISA plate at 1/250 to 1/2000
dilution in 20% Superblock-TBS (Pierce) as needed, and left
overnight, at 4uC, gently shaking. Purified primary antibodies we
added to the plate, diluted in 20% Superblock-TBS, as follow:
TG5-biotinylated 1/500000, CP27 (Ig2B) 1/20000, CP13 (IgG1)
1/20000, PHF1-biotinylated 1/10000, CP17-biotinylated 1/
20000, MC1 (IgG1) 1/20000, and left for 2 hours at room
temperature, gently shaking. Secondary antibodies, Streptavidin-
HRP or HRP-Goat-anti mouse IgG2B/IgG1, 1/5000 in 20%
Superblock-TBS (Pierce), were left on the plate for 1 hour as
above. Fifty mL of TMB (Pierce) were added and left for 209, room
temperature, light shielded, gently shaking, and the reaction was
stopped with same volume of 2M Sulfuric Acid, and read at
450nM with an automated Tecan plate reader. Every step was
followed by 5 automated washes with washing buffer (100mM
NaCl, 10mM Tris Base, 0.1% Tween20).
Western Blot
For Tau, heat stable preparations were run on a 4–12% tris-
HCl precast gel (Biorad), blotted on a 0.45mM Nitrocellulose
membrane and probed with monoclonal antibodies specific for
total Tau or site specific Tau phosphorylations as follows: DA9 (1/
3000), CP13 (1/3000CP9 (1/3000), PHF1 (1/3000), MC1 (1/
500). Antibodies were diluted in 5% milk in TBS. Western Blots
were developed either with the ECL system on film or by means of
4-Chloro-Naftol reaction on the membranes. For GSK, brains
were homogenized as described for ELISA, subjected to PAGE as
described above, and the membranes were probed with antibodies
against GSK3a/b (Santa Cruz SC-7291, 1/1000), GSK3bpSer9
(Cell Signaling #9323, 1/1000), GSK3a pTyra279/b216 (Invi-
trogen #44604G), diluted in 20% Superblock-TBS, and anti b-
Actin (Sigma-Aldrich A1978) 1/8000 in 5% Milk-TBS-
0.1%Tween20.
Immunohistochemistry
Brains were fixed in 4% PFA overnight and cut sagittally with a
vibratome the next day. Selection of corresponding sections from
each mouse was performed as follows: brains were cut sagittally at
50mM thickness, from the lateral to the medial aspect, preserving
the cerebellum. For each antibody, 3 sections were stained,
starting at section #15 (i.e. 750mM form the lateral pole), and
taking every 7
th section inward (i.e. 350mM apart from each other).
Free-floating sections were conserved in TBS (50mM Tris,
150mM NaCl, pH 7.6)/0.02%NaN3, and the staining was
performed on multiwell plates. Endogenous peroxidases were
quenched with 3% H2O2/0.25% Triton X-100/TBS for 309.
Non-specific binding was blocked with 5% Milk-TBS for 1 hour at
room temperature. Primary antibodies are as follows: NeuN
(Invitrogen #187373, 1/1000), IbA1 (WAKO #019-19741, 1/
AID Does Not Induce AD Traits
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(1/5000), PHF1 (1/5000), MC1 (1/200), all diluted in 5% Milk-
TBS, and left overnight at 4uC, shaking. Biotin-conjugated
secondary antibodies directed against the specific isotypes were
diluted 1/1000 in 20% Superblock, left for 2 hours at room
temperature, and likely Streptavidin-HRP was incubated for
1 hour. Staining was visualized by 3,39-Diaminobenzidine. Each
step was followed by 5659 washes in TBS.
Statistical analysis
All quantified data represent an average of at least triplicate
samples. Error bars represent standard errors of the mean.
Statistical analysis was done by 2-Way ANOVA and Bonferroni
Post Test. Significance was determined by Student’s t test and a
p,0.05 was considered significant.
Results
AID/hTau mice general characteristics
Mice are presenting with normal growth and weaning, thrive at
appropriate age. No significant differences were observed in
breeding and litter size and survival compared to C57BL/6 mice.
Up to 21 months of age, there is no prevalent pathology,
susceptibility to infections, and animals appear active and alert.
Tau phosphorylation and brain load are not univocally
affected by AID overexpression
Tau accumulation, phosphorylation and axonopathy can be
subtle and precede neuronal degeneration, tangle formation and
cognitive or behavioural deficits [36,37]. Thus, we have
extensively searched for any contribution of AID overexpression
to Tau pathology. We have used antibodies raised against specific
Tau phosphorylation sites that characterize early (pSer202 and
pThr231), or late (pSer396/404) stages of Tau phosphorylation in
AD [37,38]. In addition, we have also analyzed a typical
conformational change in Tau that is found at the latest stages
of AD, using the MC1 antibody. We have analyzed several mice
bearing hTau and AID50, 57 or 59, corresponding respectively to
the c-secretase e-cleavage and c-cleavage producing Ab42 or
Ab40 [27], at different ages, from 4 to 21 months. For each AID
transgene, different lines derived from distinct founders were
analyzed. Analysis of more than one AID50, 57 or 59 line is
necessary to control for phenotypes dependent on the integration
of the transgene in the mouse chromosomes, which can alter
expression of endogenous mouse genes. As previously shown, these
lines also expressed different levels of AID and they behaved
differently as far as susceptibility to toxic stimuli in vitro [27]. In the
western blot (WB) analysis (Fig. 1, Column A and quantified in
Column B), total Tau (DA9) was not significantly and consistently
altered in AID/hTau mice compared to hTau alone. Only line
57.5.1 showed an increase in total Tau at 7 months, but it was
neither confirmed in line 57.13.3, nor by the ELISA analysis
(Fig. 2, bottom panel), neither for human Tau alone, nor for
human plus mouse Tau (CP27 vs TG5).
CP13 recognizes an early Tau phosphorylation epitope
(pSer202). This phopshorylation was decreased in line 57.13.3 at
4 and 7 months on WB (Fig. 1, Column B), and also in line 57.5.1
when total Tau was accounted for (Fig. 1, Column C); contrarily,
line 50.1.5 showed an increase of CP13 signal at 13 months (Fig. 1,
Column C); ELISA data (Fig. 2) show no consistency in CP13
signal, that vary according to age and weather only human (CP27
weighed) or both human and murine (TG5 weighed) Tau are
accounted for (Fig. 2, Column A). Thr231 phosphorylation (CP9)
levels seem increased in line 59.4.4 at 4 months of age, but this
increase is not maintained later in life in WB (Fig. 1, Column C).
On the contrary, CP17 ELISA over total Tau shows an increase at
all ages for AID59.4.4 (Fig. 2, Column B). Neither AID57 line
shows consistent variation from controls at this site except a
difference between the 2 AID57 lines at 7 months. Later
phosphorylations (PHF1 Ser396/404) are not influenced by AID
overexpression. Interestinlgy, on ELISA analysis, conformationally
dependent MC1 signals show an increase in AID59 mice at 4 and
21 months (Fig. 2, Column D) when total Tau is considered. Less
consistently, MC1 signal is augmented in the AID57 lines (Fig. 1,
Column B and C; Fig. 2, Column D).
Neuronal Tau distribution is not affected by AID
overespression
Our biochemical data does not reveal a net trend of Tau
phosphorylation induced by AID overexpression. Nonetheless, we
wanted to ascertain if subtle changes could be seen at the tissue
level, in both the quantity and the distribution of Tau
phosphorylation. Furthermore, we have searched if any neuronal
loss would be evident and if any microglia activation would be
induced by AID overexpression. In Fig. 3, we show representative
hippocampal immunostaining with antibodies against total Tau
(DA9; Fig. 3A, B, C), pSer202 (CP13; Fig. 3D, E, F), pSer396/404
(PHF1; Fig. 3G, H, I). We could not detect any substantial
difference in the amount and pattern of Tau phosphorylation, in
the hippocampal area and parahippocampal cortex, attributable
to AID overexpression. When using NeuN (Fig. 3J, K) and Iba1
(Fig. 3L, M) antibodies, neither neuronal loss nor microglia
activation was seen. We did not perform unbiased stereological
neuronal counting [39], given the paucity of indications toward a
substantial loss of neurons in these mice. Microglia staining did not
show signs of either recruiting or activation [40]. Of note, these
mice show Tau distribution and phosphorylation similar to what
previously described [29].
GSK3a/b is not significantly upregulated by AID
overexpression
Although the data presented do not hint to a role for AID in
promoting Tau accumulation or deranged phosphorylation, it is
still possible that transgenic AID may cause hyperphosphorylation
of Tau at later time, by activating kinases. Another model of
AID59 overexpression [22,28] shows GSK3b activation as early as
4 months, heterogeneous Tau phosphorylation as early as 8
months, and neurodegeneration at 18 months. When we analyzed
our transgenic mice however, we could not detect any significant
and consistent activation of GSK3b (Fig. 4, column C). The AID
57 and 59 transgenic mice show some GSK3b activation at 4
months, which is however not seen in older mice.
Discussion
To directly examine the effects of AID in vivo, in the CNS, we
generated transgenic mice expressing CaMKIIa-AID, to target
AID expression to areas that are most relevant to Alzheimer’s
pathology [32]. We generated transgenic lines expressing either
the 59- 57- or 50-residue AID peptide, which would be produced
by c-cleavage together with either Ab40 or Ab42, respectively, or
the ‘‘e-cleavage’’ [41,42]. The AID50 is reputed the naturally
occurring AID fragment. We obtained two AID59 (AID59-4.4
and -1.1), four AID57 (AID57-13.3, -5.1, -5.2 and -8.1) and three
AID50 (AID50-3.4, -1.5 and 5.2) founder mice. Some of these
lines have been analyzed here (AID50.1.5, AID57 5.1 and 13.3,
AID59.4.4). When transgenic mice are used, it is important to
study lines derived from more then one founder. This precaution is
AID Does Not Induce AD Traits
PLoS ONE | www.plosone.org 3 July 2010 | Volume 5 | Issue 7 | e11609Figure 1. Western Blot analysis of Tau phosphorylation. Heat Stable Preparation of Tau, from forebrains of AID/hTau mice, were run on PAGE
(Column A) and probed with antibodies specific for total Tau (DA9), pSer202 (CP13), pThr231 (CP9), pSer396/Ser404 (PHF1) and conformational
modification of human Tau (MC1). Densitometric quantification, both raw (Column B) and over total Tau (DA9, Column C), shows no clear cut change
in the pattern of Tau phosphorylation due to AID overexpression, related neither to AID length, mouse line nor age. Experiments were repeated at
least 3 times on at least 2 mice/line. Quantifications units are arbitrary. *p,0.05; **p,0.01; ***P,0.001.
doi:10.1371/journal.pone.0011609.g001
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PLoS ONE | www.plosone.org 4 July 2010 | Volume 5 | Issue 7 | e11609Figure 2. ELISA analysis of Tau phosphorylation. Homogenate from forebrains of AID/hTau mice were anaylzed by mean of sandwich ELISA,
capturing with the total Tau DA9 antibody, and revealing with antibodies specific for total human Tau (CP27), total mouse and human Tau (TG5), or
for several Tau phosphorylations, pSer202 (CP13) (Column A), pThr231 (CP17) (Column B), pSer396/Ser404 (PHF1) (Column C) and conformational
modification of human Tau (MC1) (column D). The top 16 panels show scattered differences in the phosphorylation pattern, which do not seem to be
related to AID overexpression, length, mouse line or age. The bottom panel (E) shows how levels of total human and murine Tau are maintained in
the different mouse lines and ages. Experiments were repeated at least 3 times on at least 2 mice/line. Quantifications units are arbitrary. *p,0.05;
**p,0.01; ***P,0.001.
doi:10.1371/journal.pone.0011609.g002
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an insertional effect on endogenous mouse genes, to the transgene
itself.
A previous analysis of these mice showed that overexpression of
AID did not affect gene transcription. However, cultured neuronal
cells derived from AID transgenic mice were more sensitive to
selective apoptotic and toxic stimuli. This evidence suggests that
AID overexpression may predispose to neuronal degeneration.
Thus, we tested whether in vivo AID expression could initiate
aspects of AD that precede and lead to neuronal loss.
Contrarily to previous reports however [22,28], we failed to see
an AID-dependent activation of GSK3b and the phosphorylation
of Tau phosphorylation typical of AD. What could the basis of
these discrepancies be? There are several possibilities, which do
not need to be mutually exclusive. The findings implicating AID
in GSK3b activation and Tau pathology are based on the use of
a single mouse line, and the double transgenic model expresses an
AID molecule (AID 59) that probably does not correspond to the
one produced in vivo by processing of APP-CTFs. This is
problematic, for the reasons explained above. Although some
evidence pointed to a role of AID as a ‘‘nuclear regulator’’ per se
[43], the animal model used in these studies expresses Fe65, an
APP binding protein, together with AID 59, [44]. Thus, the
effectual contribution of AID to the described phenotypes is not
obviously clear. Mice transgenic for AID alone would have
helped, in that specific setting, to clarify the relative contribution
of Fe65 and the intracellular domain of APP to the observed
phenotypes. AID is very short lived [12] and it has been argued
that Fe65 could potentiate AID functions by stabilizing it [45].
On the other side, it has been suggested that AID, recruiting
Fe65 to the plasma membrane, is then able to release it and allow
its transcriptional function to take part in the nucleus, with or
Figure 3. Immunohistochemical analysis of AID/hTau mice. Forebrains were stained with antibodies against total Tau (DA9, A, B, C), pSer202
(CP13; D, E, F), pSer396/404 (PHF1; G, H, I), the neuronal protein NeuN (J, K) and the microglia activation protein Iba1 (L, M). The expressed AID
transgene, together with hTau, and mouse are indicated in the panels. Selected samples are representative of the analysis conducted on all AID/hTau
transgenics, at all ages. We found no significant difference in the amount and pattern of distribution of total Tau and its phosphorylations, in
hippocampal and peri-hippocampal neuronal cellularity and microglia activation between controls and AID expressing mice.
doi:10.1371/journal.pone.0011609.g003
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transcriptional control and induction of apoptosis are still
uncertain, but several facts are of note. AID overexpression in
our model is very high, as determined by Real Time PCR, and as
evident from WB analysis [27]. In particular, we have shown how
AID 57 and 59 are well expressed at the protein level, while AID
50 is not, although its mRNA is abundant. Such overexpression,
we can assume, would probably be sufficient to activate kinases
and promote Tau phosphorylation, even in the absence of Fe65
overexpression.
Figure 4. Western Blot analysis of GSK3b activation. Forebrain lysates from different lines of AID/hTau mice, at 4 different ages, were run on
PAGE (Column A) and probed with antibodies against total GSK3a and b, the inhibiting phosphorylation pSer9 and the activating phosphorylation
pTyra279/b216. Densitometric quantification over b-Actin only (Column B) and over total GSK3a/b (Column C), shows no clear cut activation or
inhibition of GSK3bby AID overexpression, related neither to AID length, mouse line nor age. Experiments were repeated at least 3 times on at least 2
mice/line. Quantifications units are arbitrary. *p,0.05; **p,0.01; ***P,0.001.
doi:10.1371/journal.pone.0011609.g004
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mechanisms underlying early pathophysiology of Alzheimer’s
disease (AD) includes axonopathy [47] and changes at synaptic
level leading to subtle amnesic symptoms at an early stage of
disease [48]. APP processing occurring in axonal extensions and/
or synapses, leading to regional production of AID, may play a
physiological role that, if disregulated, could lead to synaptic
disfunction. In transgenic animals, most of AID is produced in the
cell body, ‘‘far’’ from those neuronal compartments (axons/
synapses) were this peptide might play its pathophysiological role.
It is also likely that reduction in AID levels plays a pathogenic role
in AD. The evidence that mutations in PSEN1/PSEN2 that cause
Familial Alzheimer’s disease are loss of function mutants, and that
loss of PSEN1/PSEN2 function causes neurodegeneration in mice,
supports this hypothesis [49,50,51,52,53]. In these cases, AD
pathology coincides with lower production of total Ab, an increase
of the Ab42/Ab40 ratio, and a reduction of total AID.
In conclusion, our transgenic model shows that overexpression
of several isoforms of AID in the CNS fails to reproduce obvious
signs of AD-like pathology in mice. These data question whether a
generalized overexpression of this APP fragment can address its
role in both biology and disease if it is disjointed from the in vivo
physiopathological context in which it is generated. Given these
premises, AID and its functions should be investigated not much as
a source of AD pathology, but as a possible interesting intracellular
signaling pathway, much similar to NOTCH and NICD, that is
still obscure but highly likely to be effective in neurons, possibly
under stressing conditions.
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